Welcome to our dedicated page for Solid Biosciences news (Ticker: SLDB), a resource for investors and traders seeking the latest updates and insights on Solid Biosciences stock.
Solid Biosciences Inc. (Nasdaq: SLDB) is a Cambridge, MA-based biotechnology company focused on developing treatments and cures for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease. Solid Biosciences combines commercial acumen with top-tier science to advance promising therapies that address all aspects of DMD. The core of Solid's mission is to improve the daily lives of patients and target the roots of this debilitating condition.
The company's primary focus is on developing gene therapies and other treatments for neuromuscular and cardiac diseases. Their product pipeline includes:
- SGT-003: A next-generation gene therapy candidate for DMD, recently granted FDA clearance for an Investigational New Drug (IND) application. The therapy uses a proprietary capsid (AAV-SLB101) to deliver a microdystrophin transgene to promote muscle function and durability. The planned Phase 1/2 trial aims to evaluate the safety and tolerability of SGT-003 in pediatric patients.
- SGT-501: A treatment for catecholaminergic polymorphic ventricular tachycardia (CPVT), a fatal childhood disease.
- AVB-401: For the treatment of BAG3-mediated dilated cardiomyopathy.
- AVB-202-TT: Aimed at treating Friedreich’s ataxia.
Solid Biosciences has made significant strides in obtaining regulatory milestones. Recently, SGT-003 was granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation by the FDA, enhancing its potential marketability and support for clinical development.
The company has also been involved in strategic collaborations and financing activities. Notably, Solid entered a licensing agreement with Armatus Bio for the use of its AAV-SLB101 capsid, securing a non-exclusive worldwide license and upfront and milestone payments. In January 2024, they raised $108.9 million from a private placement to support ongoing pipeline development and business activities.
Financially, Solid Biosciences reported a net loss of $96.0 million for 2023 but expects its cash reserves and recent financing to fund strategic priorities into 2026. As of December 31, 2023, the company had $123.6 million in cash, cash equivalents, and available-for-sale securities.
For more detailed information, visit www.solidbio.com.
Solid Biosciences has announced the grant of 11,847 restricted stock units (RSUs) to a new employee. The RSUs will vest over four years, with equal installments on each anniversary of the grant date. This grant is part of the 2024 Inducement Stock Incentive Plan and aims to encourage the new hire's long-term commitment to the company. The grant complies with Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB) announced its inclusion in the Russell 3000® Index, effective July 1, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks, ranking them by market capitalization. Membership in the Russell 3000® Index grants automatic inclusion in the Russell 1000® or Russell 2000® Index, and relevant growth and value style indexes. The inclusion reflects Solid Biosciences' progress in genetic medicine for neuromuscular and cardiac diseases. As of December 2023, approximately $10.5 trillion assets are benchmarked against Russell US indexes.
Solid Biosciences, a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, announced the issuance of 30,949 restricted stock units (RSUs) to four newly hired employees. These RSUs will vest in equal installments over four years, contingent on continued service. The grants were made under the 2024 Inducement Stock Incentive Plan, following Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences reported Q1 2024 financial results and business updates, highlighting the Rare Pediatric Disease and Orphan Drug Designation for its Duchenne muscular dystrophy gene therapy candidate, SGT-003. The company plans to begin dosing in a Phase 1/2 trial in Q2 2024 with initial data expected by Q4 2024. Solid has entered a non-exclusive licensing agreement for its AAV-SLB101 capsid and maintains a strong cash position of $206.1 million, providing runway into 2026. R&D expenses decreased to $18.9 million due to prioritization of SGT-003, while net loss reduced to $24.3 million. Solid is advancing its diversified pipeline, including SGT-501 for CPVT, expected to file an IND in Q1 2025.
Solid Biosciences Inc. will present at the ASGCT 2024 Annual Meeting, showcasing advancements in AAV manufacturing, vector biology, and non-clinical data of their lead SGT-003 program. The presentations aim to highlight the company's commitment to developing genetic medicines for neuromuscular and cardiac diseases.
Solid Biosciences Inc. announced the issuance of 38,508 restricted stock units to two new employees under the 2024 Inducement Stock Incentive Plan. The RSUs will vest over four years subject to continued service with the company, in line with Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Solid Biosciences (SLDB)?
What is the market cap of Solid Biosciences (SLDB)?
What is Solid Biosciences Inc. focused on?
What are the key products in Solid Biosciences' pipeline?
What recent regulatory milestones has Solid Biosciences achieved?
How is Solid Biosciences advancing its gene therapy programs?
What is the significance of the AAV-SLB101 capsid?
How does Solid Biosciences support its financial stability?
What is Duchenne muscular dystrophy (DMD)?
What is the planned Phase 1/2 trial for SGT-003?
What are the benefits of Orphan Drug Designation (ODD)?
How can I learn more about Solid Biosciences?
